JAMA Oncology submission guide

The same avoidable issues show up repeatedly:

• treating a good specialty result as if it automatically belongs in a top-tier general oncology venue

• overinterpreting secondary endpoints or exploratory analyses

• using a title and abstract that hide the real strength or weakness of the evidence

• failing to make the clinical implication visible on the first page

• letting the supplement carry too much of the methods logic

• writing a cover letter that sounds promotional rather than editorially precise

Most of these are submission problems, not review problems. Editors can see them quickly.

What does a stronger JAMA Oncology package look like?

A stronger package usually has:

• a first page that makes the patient or practice consequence visible

• clean hierarchy between primary, secondary, and exploratory analyses

• tables that help a busy oncology editor orient immediately

• a discussion that respects limits while still arguing why the study matters

• a cover letter that explains why the paper belongs in JAMA Oncology specifically

• supplementary materials that support, but do not rescue, the main paper

That is important because many rejected papers are not weak studies. They are papers that have not yet been packaged for the level of editorial scrutiny the journal applies.

What should already be assembled before upload?

Before the file enters the system, the package should already be operationally complete enough that the editor can judge the study rather than chase missing pieces.

That usually means:

• title page, structured abstract, and Key Points already aligned around the same claim

• protocol and statistical analysis plan ready as supplemental files when required

• reporting checklists prepared for the actual study type

• disclosures, trial registration, ethics, and data-sharing language already finalized

• tables and figures edited for fast interpretation by a broad oncology editor, not just a disease-site expert

At this journal, those details are part of the credibility signal, not just admin cleanup.

What a strong cover letter includes

What practical readiness check should authors run?

Before submitting, ask these blunt questions:

1. Is the main clinical or interpretive consequence visible on page one?

1. Would the paper still look strong if the exploratory findings were removed?

1. Is the conclusion appropriately scaled to the evidence?

1. Does the package feel like a high-priority oncology submission, not just a worthy one?

If several answers are uncertain, the safer move is to strengthen the paper before upload.

Where do authors usually lose the editor?

What should you check before final submission?

Before pressing submit, make sure:

• the title and abstract state the actual implication clearly

• primary versus exploratory analyses are unmistakable

• tables support quick interpretation rather than slow decoding

• limitations are honest and visible

• the supplement supports the paper without carrying the main logic

• the cover letter makes the editorial case with discipline

At this level, strong packaging is not a cosmetic advantage. It is part of the scientific credibility signal.

How to decide whether JAMA Oncology is the right venue

When should you choose another top-tier venue?

Some papers fit better where policy, general medicine, or ultra-high-impact novelty is the primary frame. The submission decision should be driven by editorial fit, not by abstract prestige logic.

That comparison is useful because it forces the paper to justify why this is the right audience now rather than simply a desirable logo.

JAMA Oncology-specific submit signals

• the paper changes how an oncology reader thinks or acts

• the primary evidence is strong enough to stand on its own

• the package is clean, mature, and editorially focused

• the audience is broader than one narrow disease subgroup

• the manuscript looks ready for high-level scrutiny

JAMA Oncology-specific hold signals

• the abstract depends on secondary or exploratory findings for excitement

• the clinical consequence is still vague or delayed until the discussion

• the audience case is too narrow for a broad oncology title

• the methods logic is split awkwardly across the main text, tables, and supplement

• the figure package makes the paper look interesting but not yet definitive

Before you upload, run your manuscript through a JAMA Oncology submission readiness check to catch the issues editors filter for on first read.

Related JAMA Oncology resources: JAMA Oncology submission process, JAMA Oncology review time, and JAMA Oncology cover letter guide.

Is JAMA Oncology the right target for your paper?

JAMA Oncology (JIF 20.1, 5-year IF 20.1, JCR 2024) publishes roughly 122 original articles per year, making it one of the most selective oncology journals in the world. It's ranked 14th out of 326 journals in Oncology.

The journal follows AMA style and requires ICMJE compliance, structured abstracts, and Key Points. If your paper doesn't meet those structural requirements on submission day, it won't survive triage regardless of the science.

Submit here if your paper changes how a broad oncology audience interprets evidence or makes clinical decisions, the endpoint hierarchy is clean, and the reporting package is fully mature.

Choose a narrower oncology journal if the audience is genuinely one disease site, the clinical consequence requires specialist context to appreciate, or the methods logic still depends on supplementary material to hold together.

Last verified against AMA author guidelines, ICMJE recommendations, and Clarivate JCR 2024 (JIF 20.1, JCI 4.53, Q1, rank 14/326 in Oncology).

Publisher, portal, and editorial moats

JAMA Oncology runs on the manuscripts.jamaonc.com portal, the JAMA Network's manuscript-submission backbone shared across JAMA, JAMA Internal Medicine, JAMA Network Open, JAMA Cardiology, and the broader specialty family, and the JAMA Network architecture creates two journal-fit moves worth knowing before submission.

First, JAMA Network operates a coordinated cross-title transfer pathway: a JAMA Oncology desk rejection where the science is solid but the audience case is too narrow (too disease-site-specific, too policy-adjacent, or too methodologically exploratory for the flagship specialty oncology audience) can be re-routed to JAMA Network Open ($3,000 OA APC, broader scope, roughly 25 to 30 percent acceptance rate vs JAMA Oncology's roughly 8 percent) without re-uploading from scratch, and the cover letter can pre-request this transfer pathway.

Second, JAMA Oncology's published medians (3 days to first decision without external review, 33 days with review) are unusually fast for a tier-1 specialty oncology journal, which makes the package-readiness bar before upload more consequential than at slower-decision peer venues: there is no peer-review buffer to fix a weak Key Points section or scrambled endpoint hierarchy.

The journal is subscription-primary with an OA option through the JAMA Network open-access program (the published JAMA Network specialty-journal OA fee currently runs approximately $5,000 USD, lower than Cell Press / Nature Portfolio but higher than JAMA Network Open's $3,000); the OA fee is waived or institutionally covered for some funding-mandated authors via JAMA Network's Plan S Transformative Journal and read-and-publish compliance pathways.

Decision risks before submitting to JAMA Oncology

Across oncology manuscripts targeting JAMA Oncology, three recurring decision risks matter most across submissions that JAMA Oncology editors filter out at the desk-screen stage. (Per JAMA Network published policies, JAMA Oncology requires the JAMA Network structured abstract format (Importance, Objective, Design / Setting / Participants, Main Outcomes and Measures, Results, Conclusions and Relevance), Key Points with Question / Findings / Meaning, appropriate reporting checklists by study type, Word manuscript upload rather than PDF for review, and an explicit clinical-practice or evidence-interpretation significance bar.

JAMA Oncology reports an 8 percent overall acceptance rate, 3 days median to first decision, and 33 days median to first decision with review.) Use the three checks below before you open Manuscripts source page upload slot.

Key Points that restate what was measured rather than what changes oncology practice for which patient population

Across JAMA Oncology-targeted manuscripts, we consistently see authors submit packages where the Key Points (the Question / Findings / Meaning section that immediately follows the title and signals the paper's importance to editors) restate the study design rather than name the clinical-practice consequence.

JAMA Oncology editors specifically check the Key Points at desk for:

• a Question that names the clinical-decision tension (not "what is the survival benefit of X" but "should clinicians prefer X over Y for patients with characteristic Z")

• a Findings statement with the practice-changing numerical result (effect size with confidence interval, against the named comparator, in the named clinical context: "adjuvant pembrolizumab reduced 5-year recurrence by 18 percentage points (95% CI 12-24) in PD-L1-high resected NSCLC vs placebo" rather than "we performed a retrospective analysis of 850 patients")

• a Meaning statement that names the affected patient population, treatment decision, or guideline implication ("affects standard-of-care decision for approximately 40,000 US patients with PD-L1-high resected NSCLC annually" rather than "has implications for future research")

Manuscripts where Key Points describe methodology / design / cohort rather than practice-changing consequence are vulnerable during JAMA Oncology's fast first editorial screen.

The gap between "what we did" and "what changes for which patient" framing is the largest single early editorial vulnerability for methodologically sound oncology papers at this venue.

The fix is to rewrite the Key Points before submission with a Question naming the clinical-decision tension, a Findings with effect size + CI + comparator + population, and a Meaning naming the affected patient population and treatment / guideline implication.

Check whether your JAMA Oncology Key Points state the clinical consequence clearly →

Primary-endpoint inferential collapse

In Manusights reviews, we observe that JAMA Oncology submissions frequently present a paper-level conclusion that follows from a secondary endpoint, an exploratory subgroup analysis, a post-hoc biomarker-stratified subgroup, or an unplanned interim analysis when the pre-specified primary endpoint result was more modest than expected.

JAMA Network journals apply strict inferential hierarchy: the paper's conclusion must follow from the trial's pre-specified primary endpoint as registered (ClinicalTrials.gov / EudraCT / WHO ICTRP), and any conclusion based on secondary, exploratory, post-hoc, or subgroup analyses requires explicit hedging in the abstract (with "exploratory" or "hypothesis-generating" language) and explicit acknowledgment that the result requires confirmatory study.

The specific patterns JAMA Oncology editors flag at desk: biomarker-stratified subgroup result outperforming ITT analysis used as primary conclusion (PD-L1 high subgroup, MSI-high subgroup, HER2-positive subgroup, KRAS-G12C subgroup, EGFR-mutant subgroup); secondary endpoint elevated to primary in the abstract; post-hoc subgroup chosen after seeing data; multiplicity-uncorrected exploratory analyses presented without correction; survival-curve analyses without proportional-hazards verification or restricted-mean survival-time alternative; pre-specified primary endpoint reported in supplementary while secondary endpoint dominates the main paper.

Manuscripts with inferential-hierarchy collapse face desk rejection rather than reviewer debate; the editorial team prefers to redirect rather than let the issue contaminate review.

The fix is to ensure the abstract's Conclusion follows from the pre-specified primary endpoint (with effect size, CI, and p-value for the registered primary endpoint), report secondary and exploratory analyses with explicit hedging, register the trial with prespecified outcomes matching the report, apply multiplicity correction (Holm-Bonferroni / hierarchical testing / false-discovery-rate) for secondary endpoints, and verify proportional-hazards assumptions or use restricted-mean survival time when appropriate.

Check whether your JAMA Oncology conclusion follows the registered primary endpoint →

EQUATOR-checklist non-compliance

The third recurring pattern in JAMA Oncology-targeted manuscripts is reporting-checklist non-compliance even when the underlying study is methodologically sound.

JAMA Network editors specifically check at desk for:

• CONSORT 2010 compliance for RCTs (full checklist with page-and-paragraph references, sequence generation and allocation concealment described in Methods not just yes/no on checklist, blinding described for participants / care providers / outcome assessors / data analysts separately, CONSORT flow diagram with explicit enrollment / allocation / follow-up / analysis numbers, trial registration with prospectively-registered primary outcome matching report, intention-to-treat as primary with per-protocol as sensitivity)

• STROBE compliance for observational studies (eligibility criteria consistent between Methods and Supplementary Table 1, missing-data handling with proportion and method named, selection-bias and confounding sensitivity analyses)

• REMARK compliance for tumor-marker prognostic studies (assay description with named platform / antibody / threshold, training / validation cohort separation, performance metrics by predicted vs observed)

• PRISMA 2020 for systematic reviews and meta-analyses (PROSPERO prospective registration, RoB tool by design class, heterogeneity quantification)

• STARD 2015 for diagnostic accuracy (named reference standard, sensitivity / specificity with CIs)

• TRIPOD+AI for prediction models (model specification, calibration plot, decision-curve analysis)

Manuscripts where the checklist was completed after writing (as afterthought rather than structural guide) contain predictable gaps that the editorial team catches against the manuscript text before sending to review.

Manuscripts arriving with incomplete checklists or checklists inconsistent with the manuscript text face desk return during the first editorial screen.

The fix is to complete the appropriate EQUATOR checklist with explicit page-and-paragraph references before writing the manuscript so the checklist structures the writing, include the completed checklist as supplementary material at submission, ensure the Methods text matches the checklist for every item, and verify that the CONSORT flow diagram / STROBE eligibility criteria / REMARK assay description / PRISMA flow diagram have actual numbers, names, and thresholds rather than generic labels.

Check whether your JAMA Oncology manuscript is submission-ready →

Submission caps: JAMA Oncology Original Investigations cap at 3,000 words of body text, a 350-word structured abstract using JAMA Network structured headings, and a maximum of 5 figures and tables combined per JAMA Network policy. The Manuscripts source page submission portal runs ICMJE integrity checks and EQUATOR-checklist verification on upload; JAMA Oncology reports 3 days median to first decision overall and 33 days median to first decision with peer review.

Clarivate JCR 2024 bibliometric data provides additional benchmarks when evaluating journal fit.

A JAMA Oncology scope and readiness check can evaluate whether your Key Points, endpoint hierarchy, and reporting checklist alignment meet the journal's triage standard before you upload.

• the paper demonstrates clinical consequence visible on page one: changes treatment choice, risk interpretation, care delivery, or meaningful understanding of cancer outcomes for broad oncology audience

• Key Points clearly state practice-changing results rather than restating what was measured, and primary endpoint reasoning is stable and easy to follow from the endpoint hierarchy

• methodological discipline is evident: conclusions follow from pre-specified primary endpoints, subgroup reasoning is clearly flagged, and reporting aligns with guideline requirements

• the manuscript is fully mature with protocol, statistical analysis plan, ethics, trial registration, and reporting checklists ready at submission

• the abstract presents a clinical consequence that is real but confined to one narrow disease niche without convincing argument that the broad oncology audience should change practice or interpretation

• the conclusion and methods logic rely on secondary endpoints or exploratory findings because the primary endpoint result was more modest than expected

• Key Points read like a summary rather than stating the specific practice-changing consequence, or the patient consequence requires specialist context to appreciate

• tables and supplementary materials carry significant portions of the paper's logic rather than the main manuscript being stable and fully interpretable on its own